文献速递类风湿关节炎

尼泊卡利单抗(抗FcRn单克隆抗体)用于中重度活动性类风湿关节炎且对至少一种抗TNF药物应答不足或不耐受的参与者:2a期IRIS-RA研究结果

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.
PubMed 文献 · RMD Open · 2024-06-28

该2a期研究将53例抗CCP抗体或类风湿因子阳性的中重度活动性RA患者按3:2随机分配至尼泊卡利单抗组(15 mg/kg静脉注射,每2周一次)或安慰剂组,治疗至第10周。主要终点第12周DAS28-CRP较基线变化未达统计学显著,但尼泊卡利单抗组在数值上更高;所有次要疗效终点和患者报告结局均呈数值上更大改善,且基线ACPA较高者临床改善更明显。

要点

  • 主要终点第12周DAS28-CRP较基线变化未达统计学显著,尼泊卡利单抗组最小二乘均值变化为-1.03(95%CI -1.66至-0.40),安慰剂组为-0.58(95%CI -1.24至0.07)。
  • 尼泊卡利单抗显著且可逆地降低血清IgG、ACPA和循环免疫复合物水平,但未降低包括CRP在内的血清炎症标志物。
  • 3例参与者报告严重不良事件(烧伤感染、输注相关反应和深静脉血栓形成),基线ACPA较高者临床改善更明显。

核心结论

  • 尽管主要终点未达统计学显著,尼泊卡利单抗在中重度活动性RA参与者中显示出持续一致的数值疗效获益,基线ACPA较高者获益更明显。

研究设计与样本

  • 2a期研究,纳入53例对至少一种抗TNF药物应答不足或不耐受、ACPA或类风湿因子阳性的中重度活动性RA参与者,按3:2随机分配至尼泊卡利单抗组(n=33,15 mg/kg静脉注射,每2周一次)或安慰剂组(n=20),第0至10周给药。
  • 疗效终点和患者报告结局评估至第12周,安全性、药代动力学和药效学评估至第18周。

主要发现

  • 第12周DAS28-CRP较基线变化的最小二乘均值(95%CI):尼泊卡利单抗组-1.03(-1.66至-0.40),安慰剂组-0.58(-1.24至0.07),主要终点未达统计学显著。
  • 所有次要疗效终点和患者报告结局均呈数值上更高改善。
  • 尼泊卡利单抗显著且可逆地降低血清免疫球蛋白G、ACPA和循环免疫复合物水平,但未降低包括CRP在内的血清炎症标志物。
  • ACPA降低与DAS28-CRP缓解及美国风湿病学会(ACR)标准50%应答率相关;基线ACPA较高者临床改善更明显。
  • 3例参与者报告严重不良事件:烧伤感染、输注相关反应和深静脉血栓形成。

关键数值与推荐

  • 主要终点为第12周DAS28-CRP较基线变化。
  • 尼泊卡利单抗给药方案为15 mg/kg静脉注射,每2周一次,第0至10周。
  • ACPA降低与DAS28-CRP缓解及ACR 50%应答率相关;基线ACPA较高者临床改善更明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要终点未达统计学显著。
  • 原文结论指出尼泊卡利单抗显示出数值疗效获益,基线ACPA较高者获益更明显,但主要终点未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of nipocalimab in participants with moderate to severe active rheumatoid arthritis (RA) and inadequate response or intolerance to ≥1 antitumour necrosis factor agent. METHODS: In this phase 2a study, participants with RA seropositive for anticitrullinated protein antibodies (ACPA) or rheumatoid factors were randomised 3:2 to nipocalimab (15 mg/kg intravenously every 2 weeks) or placebo from Weeks 0 to 10. Efficacy endpoints (primary endpoint: change from baseline in Disease Activity Score 28 using C reactive protein (DAS28-CRP) at Week 12) and patient-reported outcomes (PROs) were assessed through Week 12. Safety, pharmacokinetics and pharmacodynamics were assessed through Week 18. RESULTS: 53 participants were enrolled (nipocalimab/placebo, n=33/20). Although the primary endpoint did not reach statistical significance for nipocalimab versus placebo, a numerically higher change from baseline in DAS28-CRP at Week 12 was observed (least squares mean (95% CI): -1.03 (-1.66 to -0.40) vs -0.58 (-1.24 to 0.07)), with numerically higher improvements in all secondary efficacy outcomes and PROs. Serious adverse events were reported in three participants (burn infection, infusion-related reaction and deep vein thrombosis). Nipocalimab significantly and reversibly reduced serum immunoglobulin G, ACPA and circulating immune complex levels but not serum inflammatory markers, including CRP. ACPA reduction was associated with DAS28-CRP remission and 50% response rate in American College of Rheumatology (ACR) criteria; participants with a higher baseline ACPA had greater clinical improvement. CONCLUSIONS: Despite not achieving statistical significance in the primary endpoint, nipocalimab showed consistent, numerical efficacy benefits in participants with moderate to severe active RA, with greater benefit observed for participants with a higher baseline ACPA. TRIAL REGISTRATION NUMBER: NCT04991753.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Taylor PC, Schett G, Huizinga TW, et al. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 2024. PMID: 38942592. doi:10.1136/rmdopen-2024-004278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。